Please assess the completion status of the following clinical trial:

Trial Title: Cost- Effectiveness and Quality of Life Assessment in Mood Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. ages between 18 and 65;~2. BD current acute mixed episode;~3. total capacity to understand and respond to self-applied instruments;~4. the presence of symptoms in the last 30 days;~5. abstinence for at least 30 days for drug addicts.~Exclusion Criteria:~1. presence of Organic Brain Syndrome (OBS);~2. pregnancy or lactation;~3. criteria for psychiatric hospitalization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lithium (Type: ACTIVE_COMPARATOR): Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (A) Started Lithium (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~1. First step: Monotherapy with Lithium (900-1500mg) Non responsive patients: 2nd step.~2. Second step: Randomization for lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) OR lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~   Non responsive patients: 3rd step.~3. Third step: Crossover lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) X lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~   Non responsive patients: 4th step.~4. Fourth step: Association with risperidone (1-6mg)
- Acid Valproic (Type: ACTIVE_COMPARATOR): Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (B) Started Valproic Acid (1000mg-1500mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~1. First step: Monotherapy with Valproic Acid (1000mg-1500mg) Non responsive patients: 2nd step.~2. Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~3. Third step: Crossover: lithium (900mg-1500mg) + carbamazepine (600mg-1200mg). Non responsive patients: 4th step.~4. Fourth step: Association with risperidone (1-6mg)
- Carbamazepine (Type: ACTIVE_COMPARATOR): Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (C) Started Carbamazepine (600mg-1200mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~1. First step: Monotherapy with Carbamazepine (600mg-1200mg). Non responsive patients: 2nd step.~2. Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~3. Third step: Crossover: lithium (900mg-1500mg) + valproic acid (1000mg-1500mg). Non responsive patients: 4th step.~4. Fourth step: Association with risperidone (1-6mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).